• Combination Treatment for Visceral Leishmaniasis Patients Co-infected with Human Immunodeficiency Virus in India

      Mahajan, Raman; Das, Pradeep; Isaakidis, Petros; Sunyoto, Temmy; Sagili, Karuna D; Lima, Marıa Angeles; Mitra, Gaurab; Kumar, Deepak; Pandey, Krishna; Van Geertruyden, Jean-Pierre; et al. (Oxford University Press, 2015-06-30)
      There are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are at higher risk of relapse and death, but there are still no evidence-based guidelines on how to treat them. In this study, we report on treatment outcomes of co-infected patients up to 18 months following treatment with a combination regimen.
    • Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

      Sinha, Prabhat K; van Griensven, Johan; Pandey, Krishna; Kumar, Nawin; Verma, Neena; Mahajan, Raman; Kumar, Pankaj; Kumar, Ranjeet; Das, Pradeeb; Mitra, Gaurab; et al. (Oxford University Press, 2011-10)
      Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection. We report the 2-year treatment outcomes of VL-HIV-coinfected patients treated with liposomal amphotericin B followed by combination antiretroviral treatment (cART) in Bihar, India.
    • Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome).

      Burza, Sakib; Mahajan, Raman; Sinha, Prabhat K; van Griensven, Johan; Pandey, Krishna; Lima, María Angeles; Sanz, Marta Gonzalez; Sunyoto, Temmy; Kumar, Sunil; Mitra, Gaurab; et al. (PLoS, 2014-08-07)
      Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20-25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.